Equities research analysts expect MediWound Ltd. (NASDAQ:MDWD) to announce sales of $5.70 million for the current quarter, Zacks reports. Two analysts have provided estimates for MediWound’s earnings, with the lowest sales estimate coming in at $5.50 million and the highest estimate coming in at $5.89 million. MediWound reported sales of $4.03 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 41.4%. The firm is scheduled to announce its next earnings results on Thursday, August 5th.
According to Zacks, analysts expect that MediWound will report full year sales of $26.56 million for the current fiscal year, with estimates ranging from $23.21 million to $29.90 million. For the next financial year, analysts anticipate that the business will report sales of $20.68 million, with estimates ranging from $19.20 million to $22.15 million. Zacks’ sales averages are a mean average based on a survey of analysts that that provide coverage for MediWound.
MediWound (NASDAQ:MDWD) last released its quarterly earnings data on Wednesday, May 5th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.02. The business had revenue of $5.85 million during the quarter, compared to analyst estimates of $5.30 million. MediWound had a negative return on equity of 125.38% and a negative net margin of 41.37%.
MDWD traded down $0.02 on Friday, reaching $4.25. The company had a trading volume of 3,319 shares, compared to its average volume of 982,698. The stock has a market cap of $115.77 million, a P/E ratio of -12.62 and a beta of 1.53. MediWound has a one year low of $2.90 and a one year high of $6.22. The firm has a fifty day moving average of $4.14.
Several institutional investors have recently bought and sold shares of the company. Marshall Wace LLP purchased a new stake in shares of MediWound during the 1st quarter worth about $93,000. Wells Fargo & Company MN increased its stake in shares of MediWound by 7.4% during the 4th quarter. Wells Fargo & Company MN now owns 265,247 shares of the biopharmaceutical company’s stock worth $981,000 after purchasing an additional 18,390 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of MediWound by 1.1% during the 4th quarter. Renaissance Technologies LLC now owns 648,422 shares of the biopharmaceutical company’s stock worth $2,399,000 after purchasing an additional 7,300 shares during the last quarter. Essex Investment Management Co. LLC acquired a new position in shares of MediWound during the 4th quarter worth $982,000. Finally, Virtu Financial LLC bought a new stake in shares of MediWound during the 4th quarter worth about $41,000. Institutional investors and hedge funds own 17.90% of the company’s stock.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Featured Article: Earnings Reports
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.